Duchenne muscular dystrophy (DMD) is an incurable genetic disease with early mortality. Multipotent mesenchymal stromal cells (MSCs) are of interest because of their ability to differentiate to form myogenic cells in situ. In the present study, methods were developed to expand cultures of MSCs and to promote the myogenic differentiation of these cells, which were then used in a new approach for the treatment of DMD. MSC cultures enriched in CD271 + cells grew better than CD271-depleted cultures. The transduction of CD271 + MSCs with MyoD caused myogenic differentiation in vitro and the formation of myotubes expressing late myogenic markers. CD271 + MSCs in the myogenic cell lineage transplanted into dog leukocyte antigen (DLA)-identical dogs formed clusters of muscle-like tissue. Intra-arterial injection of the CD271 + MSCs resulted in engraftment at the site of the cardiotoxin (CTX)-injured muscle. Dogs affected by X-linked muscular dystrophy in Japan (CXMD J ) treated with an intramuscular injection of CD271 + MSCs similarly developed muscle-like tissue within 8-12 weeks in the absence of immunosuppression. In the newly formed tissues, developmental myosin heavy chain (dMyHC) and dystrophin were upregulated. These findings demonstrate that a cell transplantation strategy using CD271 + MSCs may offer a promising treatment approach for patients with DMD.
IntroductIon
Duchenne muscular dystrophy (DMD) is a severe X-linked muscle disease in which mutations in the gene encoding the cytoskeletal protein dystrophin result in a deficiency of the dystrophin-glycoprotein complex of the sarcolemma. 1, 2 The deficiency causes the progressive degeneration of striated muscle, manifesting as muscle weakness and eventual skeletal muscle atrophy. 3, 4 Cell-based therapy for DMD has the potential to restore dystrophin expression and therefore also the muscle parenchyma. The transplantation of normal stem cells, such as hematopoietic stem cells, myoblasts, and muscle-derived stem cells, has been examined as a possible treatment strategy for DMD and as a system to deliver therapeutic recombinant proteins to target muscle tissues. [5] [6] [7] Indeed, the intramuscular or intravenous injection of these cells was shown to improve the disease phenotype in the mdx mouse model. 8 Bone marrow stem cells have been shown to participate in the regeneration of injured muscle. 9, 10 Bone marrow mesenchymal stem cells (MSCs) are conventionally defined as adherent nonhematopoietic (NH) cells expressing several common cell-surface antigenic markers, such as CD44, CD73, CD90, and CD105, but not the hematopoietic markers CD34 and CD45. 11 After treatment with inducing agents, 12 MSCs can differentiate in vitro into adipocytes, chondrocytes, and osteocytes, but also into neurons, hepatocytes, pancreatic islets, and muscle. 13 In mdx mice, transplanted adult human MSCs were incorporated into myofibers with the subsequent restoration of dystrophin expression. [14] [15] [16] However, no therapeutic strategy using MSCs has proven successful for models of DMD in mid-sized animals, such as the dog. Moreover, while successful cell therapy in canine muscular dystrophy has been demonstrated using heterologous mesoangioblasts, 17 the development of an analogous approach for clinical use in humans has been hindered by the inability to overcome several obstacles, including poor cell survival rates, limited dissemination of injected cells, immune responses to allogeneic cells, the presence of the neotransgene product in dystrophic muscle, and the inability to specifically target the cells, such as to cardiac tissue. example, they can induce the myogenic differentiation of neighboring satellite cells in the interstitial tissue. 19 Nonetheless, the transplantation of cells already induced to differentiate along the pathway of interest would seem to offer a more direct and readily controllable therapeutic approach than conventional strategies that rely on the innate properties of MSCs to target undifferentiated cell populations. Here, we demonstrate that CD271-enriched (+) MSCs isolated from bone marrow showed improved growth expansion in culture and, as evidenced by MyoD expression, myogenic conversion. CD271 is a marker of progenitor cells and a specific marker for bone-marrow-derived MSCs. 20 Our study describes the development of CD271 + MSC expanded cultures, the myogenic differentiation of these cells, and the methods used to achieve their delivery and effective cell transplantation. Successful engraftment was achieved with CD271-enriched (+) MSCs injected by either the intramuscular or the systemic, intraarterial route in littermate donor-recipient pairs of dogs with dog leukocyte antigen (DLA) identity 21 (wild-type dogs) as well as in a Beagle with canine X-linked muscular dystrophy in Japan (CXMD J ), 22 in which a splice-acceptor site mutation in intron 6 of the DMD gene leads to the failed expression of dystrophin. 23 This is the first report of a protocol for the preparation of dog MSCs and the successful long-term engraftment of CD271 + MSCs with a myogenic lineage. This cell-based therapeutic strategy merits further investigation for clinical use in DMD patients.
results
Isolation and characterization of cd271 + Mscs from canine bone marrow Canine bone marrow cells were isolated from biopsy specimens from donor Beagle dogs. Since bone marrow MSCs are difficult to expand in culture, they were enriched for CD271 + cells using an immunomagnetic column system (Figure 1a ) to obtain a subpopulation of cells with better growth potential, which are thus more readily expandable for use in transplantation (Figure 1b) . Both CD271 + and CD271 − MSCs demonstrated a fibroblast-like morphology after monolayer growth expansion in vitro (data not shown). Flow cytometry analysis showed that CD44 + and CD90 + cells were present in the CD271 + fraction, whereas CD45 + cells were limited to the CD271 − fraction (Supplementary Figure S1a) . We then tested whether CD271 + MSCs were able to differentiate into adipogenic, chondrogenic, and osteogenic cell lineages (Figure 1c) . Adipogenesis was evidenced by the accumulation of neutral lipid vacuoles that stained with Nile red. Characteristic morphological changes and toluidine blue staining were indicative of chondrogenesis. Osteogenesis was confirmed by an increase in alkaline phosphatase activity. Whereas the CD271 expression on MSCs decreased after 4 weeks in culture (Supplementary Figure  S1b) , these cells retained their ability to differentiate into adipocytes, chondrocytes, and osteoblasts. Similar results were also obtained for dystrophic CD271 + MSCs (Supplementary Figure  S2) , which suggested that CD271-enriched canine MSCs are capable of growth expansion as well as differentiation into multiple cell lineages.
Myod-mediated myogenic differentiation of canine cd271 + Mscs CD271 + MSCs from wild-type or DMD dogs were tested for myogenic conversion following their in vitro transduction with MyoD, which was transiently expressed from an adenovirus vector (Ad-MyoD). Efficient adenovirus infection requires coxsackie-adenovirus receptor and α(v) integrin. The efficiency of adenovirus-mediated transgene expression 24 is improved by increasing coxsackie-adenovirus receptor expression, which is achieved by treating the transduced cells with the histone deacetylase inhibitor FK228 24 hours before infection. 24 As shown in Figure 2a , this resulted in a dose-dependent enhancement of infection, as confirmed in CD271 + MSCs transduced with an adenovirus vector expressing enhanced green fluorescent protein (Ad-eGFP). Indeed, 2 days after Ad-MyoD transduction of CD271 + MSCs in the presence of FK228, >90% of the CD271 + MSCs expressed MyoD in the nucleus, as shown with an anti-MyoD antibody (Figure 2b) , whereas no MyoD signal was observed in the cells transduced with the control Ad-eGFP vector (data not shown). Several markers of myogenesis, such as myogenin, developmental myosin heavy chain (dMyHC) and dystrophin, were detected in the MyoD-transduced CD271 + MSCs using reverse transcriptase-PCR (Figure 2c ). After 14 days of culture in differentiation medium, multinucleated myotube formation was noted. These results demonstrated that Ad-MyoD-transduced CD271 + MSCs had undergone myogenic differentiation (Figure 2d ), suggesting that MyoD is able to initiate myogenesis of CD271 + MSCs.
transplantation of cd271 + Mscs into dlA-identical dogs by intramuscular injection
To test whether the MyoD-transduced CD271 + MSCs contributed to muscle regeneration, allogeneic CD271 + MSCs were transplanted into DLA-identical donor-recipient pairs of dogs, described in MSCs transduced with MyoD and luciferase into the cardiotoxin (CTX)-injured tibialis anterior (TA) muscle (2 × 10 6 cells/injection). Eight weeks after transplantation, CD271 + MSC clusters were observed at the injection site of the muscle, as determined using fluorescence microscopy and anti-luciferase antibody. In addition, CD271 + MSCs gave rise to dystrophin-positive fibers (21/4,872 fibers, 0.4%) in the CTX-injured TA muscle (Figure 3 ).
Widespread engraftment of cd271 + Mscs by intra-arterial injection
Next, we examined whether systemic arterial injection of CD271 + MSCs resulted in their ultimate distribution in muscle. As described in Materials and Methods, the dogs used in these experiments were administered immunosuppressants, which did not cause any side effects either during or after treatment. The TA muscles of three wild-type dogs were treated with CTX. Five days later, 5 × 10 8 CD271 + MSCs transduced with MyoD and eGFP were injected into the dogs' femoral artery. For more effective cell engraftment, prior to the injection the artery was treated with papaverine, a clinically used blood vessel relaxant that increases blood flow to the heart and throughout the body. Eight weeks after the transplantation, eGFP + myofibers (7/216 fibers, 3.2%) derived from the donor were distributed in the TA muscle (Figure 4a ) and in the heart (Supplementary Figure S3) . Most of these eGFP + fibers expressed dMyHC, which is normally transiently re-expressed in regenerated muscle after injury or in response to disorders involving skeletal muscle. 25 This result suggested that the muscle fibers had regenerated following injury. PCR analysis of eGFP gene expression in various dog tissues detected donor cells at the injected hindlimb, the right TA and right extensor digitorum longus muscles, and in the heart, but not in the diaphragm, liver, kidney, or lung (Figure 4b ). In addition, eGFP expression was higher in dogs whose femoral arteries were pretreated with papaverine hydrochloride than in dogs not treated with the drug. Neither ectopic tissue formation nor tumor development occurred after transplantation. There was no increase in acute-phase C-reactive protein levels in the recipient dogs during the experiments, suggesting the absence of a severe inflammatory response (data not shown). Other biochemical tests confirmed normal liver and kidney function and that there was no reaction to the intra-arterial injection of CD271 + MSCs (data not shown). These results indicate that the intra-arterially injected CD271 + MSCs are capable of long-term survival and widespread tissue engraftment, without adverse consequences for the transplanted animal. Furthermore, successful engraftment of CD271 + MSCs in DLAidentical dogs was achieved not only by the intramuscular but also by the intra-arterial route of injection.
long-term engraftment and myogenic lineage of cd271 + Mscs in dystrophic dogs without immunosuppression
Based on the encouraging results obtained in wild-type dogs, we asked whether the same results, i.e., MyoD expression, could be obtained in DMD dogs. In addition, due to the well-known side Eight weeks after transplantation, the muscles were biopsied. Microscopy cross-sections of the muscles were prepared and then analyzed by immunofluorescence staining with luciferase (red), dystrophin (green), and 4′, 6′-diamidino-2-phenylindole (DAPI) (blue), which revealed luciferase and dystrophin double-positive muscle fibers (arrow and *). High-magnification images (lower panels) were from the boxed region in the upper panel. effects associated with the use of immunosuppressants (cyclosporine and mycophenolate mofetil), we decided to transplant the cells into DMD dogs without immunosuppression. CD271 + MSCs transduced with luciferase and MyoD (4 × 10 6 cells) were injected into the TA muscles of CXMD J in the absence of immunosuppression. Eight weeks later, numerous clusters of luciferase-positive cells (188/9,408 fibers, 2.0%) with several centrally located nuclei were detected in the TA muscle by immunohistochemistry (Figure 5a) . The mean diameters of the luciferase-positive cells (8 weeks after transplantation, 33.6 ± 10.7 μm; 12 weeks after transplantation, 47.6 ± 12.0 μm) were smaller than those of the untreated muscle fibers (95.4 ± 23.3 μm). Twelve weeks later, the diameters of the luciferasepositive cells had increased and were larger than observed 8 weeks after transplantation (Figure 5b) .
To identify whether the smaller cells found in the treated muscles were of a myogenic lineage, dMyHC expression was analyzed. Merged images showed that the luciferase-positive fibers (95% positivity) also expressed the skeletal muscle isoform of dMyHC (Figure 5a) . Reverse transcriptase-PCR analysis and immunohistochemical experiments demonstrated the expression of myogenin, dMyHC, and dystrophin (Figure 5c ). Dystrophin expression was also confirmed in wild-type donor-derived cells at the engrafted site, although the number of dystrophin-positive cells was relatively small (Figure 5d) .
Hematoxylin and eosin staining of the CD271 + MSCs-injected muscles showed cellular infiltrates around degenerating fibers (Figure 5a) . The infiltrates were also detected using antibodies directed against CD8 and CD11b, indicative of lymphocytes and macrophages, respectively. As shown in Figure 5e , small CD8 + and CD11 + T cells accumulated close to the luciferase-positive myofibers. Twelve weeks after engraftment, these accumulations decreased in size compared to those observed in muscle biopsied 8 weeks after transplantation (Supplementary Figure S4) . Immunoblot analysis failed to detect anti-dystrophin antibodies (Supplementary Figure S5 and Supplementary Materials and Methods), implying that they were not produced in the recipient dogs. Dog sera were also tested for the presence of neutralizing antibody to adenovirus type 5. 26 Transplanted dogs initially negative for neutralizing antibody levels remained negative, with titers <1:4. Mean serum creatine kinase, and C-reactive protein also did not increase during the experiment.
These results demonstrated that transplanted CD271 + MSCs expressing MyoD were converted to myogenic cells and fused with existing muscle fibers, and then formed myotubes in muscle tissue. Moreover, engraftment, differentiation, and the long-term survival of myogenic cells were accomplished by the transplantation of CD271 + MSCs into dystrophic skeletal muscle in the absence of immunosuppression.
dIscussIon
To develop a new strategy for the cell-based therapy of DMD, we examined methods for the in vitro expansion and myogenic differentiation of CD271 + MSCs, using these cells in the allogeneic transplantation of dogs. The enrichment procedure yielded a large population of canine CD271 + MSCs that could be induced to differentiate into myogenic cells following the transient expression of MyoD. Long-term engraftment of CD271 + MSCs within muscle tissues was successfully accomplished by either intramuscular or intra-arterial injection of myogenic cells into DLA-identical dogs.
The effective therapeutic use of MSCs requires their relatively simple large-scale production and a method to induce their differentiation along a myogenic lineage. CD271 provides a marker for the enrichment of non-HSCs from bone marrow aspirates. 20, 26 Canine MSCs were obtained from the bone marrow of wild-type or CXMD J in amounts sufficient for transplantation experiments by enriching the subpopulation of CD271 + cells, as previously reported for humans, 27 under conditions in which the capacity of these cells for multipotent differentiation was maintained. We hypothesized that the CD271-enriched fraction of MSCs would promote allogeneic as well as autologous cells transplantation. CD271 is also known as the low-affinity nerve growth factor receptor/p75, which plays a key role in satellite cell function. 28 Nerve growth factor acts through its low-affinity CD271 receptor to induce a developmentally regulated signaling pathway necessary for myogenic differentiation and muscle repair in vivo. Therefore, it was presumed that CD271 would enhance the in vivo myogenic differentiation of MSCs to form muscle fibers. Recombinant adenovirus transduction of MSCs usually occurs with low efficiency, which limits its utility. Therefore, improved adenovirus-mediated transduction in vitro was achieved by pretreating CD271 + MSCs with the histone deacetylase inhibitor (FK228), 29 which resulted in the efficient expression of MyoD and, subsequently, myogenic differentiation of the cells.
Other agents that induce the differentiation of MSCs, such as 5-azacytidine 30 and Notch I intracellular domain, 16 are known to be injurious to primary cultured cells. Here, we showed that MyoD expression triggers the myogenic differentiation of CD271 + MSCs. These cells maintained their multipotent characteristics, including their myogenic potential, and were successfully used for transplantation in dogs. Furthermore, MyoD transduction of CD271 + MSCs was shown to cause their myogenic differentiation with the induced expression of the late myogenic markers myogenin, dMyHC and dystrophin, although multinucleated myotube formation was less efficient. These results demonstrate that MyoD expression is able to trigger myogenic differentiation of CD271 + MSCs and that, after cell transplantation in muscle tissue, MyoDtransduced MSCs fuse with myoblasts to form the final differentiated myofibers.
MyoD has also been shown to trigger myogenic conversion in other cell types. 31 For example, telomerase gene transfer was used to transduce MyoD into immortalized fibroblasts, which were then engrafted into regenerating muscle, demonstrating that dystrophin rescue is achieved ex vivo as well as in vivo. 32 However, the potential for ectopic tissue formation and cell tumorigenicity remains a concern. To avoid immune-mediated cell rejection, DLA-identical dogs were transplanted with allogeneic CD271 + MSCs. These MyoDtransduced CD271 + MSCs were able to efficiently engraft and then develop along a myogenic cell lineage in the muscle tissue of the recipient dog. The use of allogeneic cell types generally requires long-term immunosuppression to prevent immune-mediated rejection of the transplanted cells. 33, 34 However, in this study, the long-term engraftment of CD271 + MSCs was successful whether or not the DLA-identical dogs were treated with immunosuppressants after transplantation. Although immunohistochemistry revealed several inflammatory infiltrates, mainly containing macrophages, in the recipient muscle of the CXMD J , the majority of CD271 + MSCs migrated into only transient, mild inflammatory foci. The infiltrations were observed at 8 weeks after transplantation but were less abundant after 12 weeks. Our results contrast with those obtained following the transplantation of heterologous mesoangioblasts in golden retrievers with muscular dystrophy, in which the use of immunosuppressants, such as cyclosporine and rapamycin, was required for dystrophin expression. 17 In another study, the intramuscular injection of bone marrow cells in littermate recipients rendered tolerant to the cells did not lead to the production of new myofibers. 35 The successful induction of dystrophin expression achieved in our experiments may have been due to the anti-inflammatory and immunosuppressive properties of MSCs, which inhibit T-cell proliferation. Mechanistically, MSCs are known to inhibit tumor necrosis factor-α secretion and to promote interleukin-10 secretion, which together may affect the maturation state and functional properties of dendritic cells and skew the immune response towards an anti-inflammatory/tolerant phenotype. 36 Alternatively, the presence of MSCs in an inflammatory microenvironment inhibits interferon-γ secretion from T H 1 and NK cells and increases interleukin-4 secretion from T H 2 cells, thereby promoting a T H 1-T H 2 shift and thus an increase in the proportion of regulatory T-cells. However, once MSCs differentiate into skeletal muscle, they may lose their immunosuppressive properties. Nonetheless, the differentiated cells might be invisible to the host's immune system because of their low-level expression of HLA class I. This would allow the long-term engraftment of CD271 + MSCs without rejection by the DLA-identical CXMD J recipient following immunosuppressant-free transplantation.
The safety and utility of MSCs underlines their potential clinical benefits. Indeed, the infusion of MSCs has been shown to relieve immune-mediated complications, as reported in patients with severe acute graft versus host disease (GVHD). 37 However, in a phase III trial, a single infusion of MSCs at the time of transplantation did not prevent the development of GVHD in major histocompatibility complex-mismatched donor-recipient pairs. There was also no significant difference in the incidence of GVHD between patients receiving MSCs and the controls. 38 Therefore, further studies aimed at improving the immunosuppressive function of MSCs are needed. In a combined approach, a DMD patient was treated with MSC-like endometrial regenerative cells, CD34 umbilical cord blood, and mixed lymphocyte reaction-matched positive cells, which resulted in improvements in muscular strength and clinical respiratory function. 19 Although these improvements were ascribed to the anti-inflammatory properties of MSCs, our cell transplantation strategy with subsequent myogenic differentiation offers a more direct form of therapy and thus may well be more effective.
In the transplanted CXMD J , most of the CD271 + MSCderived muscle fibers expressed dMyHC and myogenin. Indeed, MSCs can fuse with dystrophic muscle and produce trophic factors that augment the activity of endogenous myosatellite cells. 19, 39 Because myogenin is deeply associated with myotube differentiation, our result suggested that the engrafted cells were committed to differentiate, and some of them were even dystrophin-positive. The infiltration of CD8 + and CD11 + T cells might explain the low number of dystrophin-positive fibers; however, it may be that dystrophin expression and fiber formation by MSCs-derived myotubes is a long-term event. Indeed, dystrophin expression was induced in MSC-like dental pulp stem cells one year after their transplantation in golden retrievers with muscular dystrophy littermates, whereas only a small number of fibers were detected 3 months after transplantation. 40 Thus, our method requires continued studies to determine the efficiency of post-transplantation dystrophin expression by MyoD-transduced CD271 + MSCs. Future studies might also include the modification of the immunosuppressive function of MSCs to further improve engraftment efficiency and differentiation.
The low efficiency of widespread engraftment and differentiation of intramuscularly injected cells is clearly inadequate for the effective treatment of large muscles. To overcome this problem, we devised a strategy in which the intra-arterial injection of cells allowed the widespread engraftment of the CD271 + MSCs in CTX-injured muscle and in the heart. It therefore seems likely that MSCs selectively accumulate in injured muscles, 41 perhaps in response to various chemokine signals, such as stromal cellderived factor 1 or macrophage/monocyte chemotactic protein-3, both of which are associated with the migration of MSCs into injured tissues. 42 To our knowledge, this is the first report demonstrating the potential for systemic delivery of MSCs to injured tissues in dogs.
In conclusion, the work described herein offers a method to isolate and expand canine bone-marrow-derived CD271 + MSCs in vitro. Since MSCs have anti-inflammatory properties, long-term engraftment in dog muscle was facilitated by the intramuscular or intra-arterial injection of CD271 + MSCs into DLA-identical dogs, which obviated the need for immunosuppression. Finally, MyoD expression was able to direct the myogenic differentiation of CD271 + MSCs in dog muscle. Further development of this approach is needed to obtain fully differentiated adult muscle cells from undifferentiated fetal cells.
In addition to their ability to regenerate muscle tissue, MSCs can be used to produce vectors for efficient gene delivery to target tissues. 43, 44 For example, MSCs producing recombinant adeno-associated virus (rAAV) can effectively express the gene products at sites of inflammation. In fact, it was also reported that rAAV2 or rAAV6 delivery to the striated muscles of a nonimmunosuppressed canine recipient resulted in insufficient transgene expression but strong immune responses, 45 although Gregorevic et al. reported that the administration of rAAV carrying the microdystrophin gene restored specific muscle force and extended the lifespan of dystrophic mice. 46 Also, dystrophin-specific T cells were detected after the treatment of DMD patients with functional rAAV that encoded dystrophin. 47 MSCs producing rAAV-microdystrophin would be beneficial in autologous cell transplantation for DMD treatment if the immune reactions were inhibited by specifically using immunosuppressive CD271 + MSCs for transduction.
MAterIAls And Methods
Production and vector transduction. The canine MyoD genome or eGFP complementary DNA was inserted into the adenoviral vector AVC2.null DNA-protein complex through homologous recombination using an In-Fusion Dry-Down PCR cloning kit (Takara Bio, Shiga, Japan) according to the manufacturer's instructions. 48 The resultant recombinant adenovirus vectors (Ad-cMyoD, Ad-eGFP, and Ad-null) were propagated in 293 cells and purified by two-tier CsCl gradient centrifugation. Viral titers were determined based on the 50% tissue culture infective dose (TCID 50 ). To generate the vesicular stomatitis virus-glycoprotein (VSV-G)-pseudotyped retroviral vector encoding firefly luciferase (RV-Luc) or eGFP (RV-eGFP), HEK-293 cells were transduced with pDNLuc or pDNeGFP, pGag-pol 49 and pVSV-G. 49 The culture supernatant was collected 48 hours later and centrifuged to enrich the recombinant retrovirus, which was further purified using an ion-exchange procedure. 44 MSCs were transduced with RV-eGFP or RV-Luc and Ad-cMyoD or control Ad-null at a multiplicity of infection of 10 or 50.
Animals. All animals were housed in the National Center of Neurology and Psychiatry (Tokyo, Japan). DLA-identical littermate donor/recipient pairs (n = 6) were matched at DLA class II (DRB-1, DQA-1, DQB-1). Male and female wild-type dogs, 2-16-months-old, were obtained from the Beagle-based CXMD J breeding colony at the National Center of Neurology and Psychiatry (Tokyo, Japan) and used as recipients or donors for cell transplantation. Age-matched CXMD J were used as donors for cell transplantation. All of the animals were cared for and treated in accordance with the guidelines approved by the Ethics Committee for the Treatment of Laboratory Animals at National Center of Neurology and Psychiatry which has adopted the three fundamental principles of replacement, reduction, and refinement.
Bone marrow aspiration and isolation of canine MSCs. Donor wildtype dogs were anesthetized with thiopental and isoflurane, and then 1.0 ml of bone marrow fluid was obtained from each humerus by aspiration with a syringe containing 2 ml of RPMI-1640 culture medium (Invitrogen, Carlsbad, CA) with 16 mmol EDTA-2Na. Mononuclear cells were isolated by density centrifugation using Histopaque-1077 (SigmaAldrich, St Louis, MO). CD271 + MSCs were enriched and cultivated by using the MSC Research Tool Box-CD271 (LNGFR) containing CD271 (LNGFR)-PE and Anti-PE Micro Beads for cell separation (Miltenyi Biotec, Bergisch Gladbach, Germany). The percentage of CD271 + cells in the enriched and depleted cell fractions was assessed by flow cytometry (FACS Canto II; BD Biosciences, San Jose, CA). Each of the cell fractions was cultured with NH expansion medium (Miltenyi Biotec) supplemented with 100 U penicillin/ml and 100 μg streptomycin (SigmaAldrich)/ml and cultured at 37 °C in a humidified 5% CO 2 -containing atmosphere.
Differentiation of MSCs.
The differentiation of CD271 + MSCs into adipocytes, chondrocytes, and osteoblasts was analyzed in vitro after 2 or 4 weeks of culture in NH differentiation medium. To confirm adipogenesis and chondrogenesis, cells cultured for 4 weeks in differentiation medium in 24-well plates (IWAKI, Tokyo, Japan) were fixed in 1% formaldehydephosphate-buffered saline (PBS) for 1 hour at 4 °C, permeabilized in PBS containing 0.1% Triton X-100 for 5 minutes, and then washed twice with PBS. The cell monolayers were incubated with 100 ng Nile red (Invitrogen)/ µl for 1 hour or toluidine blue for 30 minutes at room temperature, and washed twice with PBS. For osteogenesis, cells that had been cultured for 4 weeks in differentiation medium in 24-well plates were fixed in cold methanol for 5 minutes at −20 °C and then washed twice with dH 2 O. The cell monolayers were incubated with 2 ml of alkaline phosphatase BCIP/NBT (Sigma-Aldrich) for 10 minutes at room temperature and washed twice with PBS. cells/well) plated on collagen-coated coverslips (IWAKI) in 24-well plates were exposed to 3.3 ng of the histone deacetylase inhibitor FK228 (Astellas Pharma, Tokyo, Japan) per ml of NH expansion medium for 7 hours at 37 °C. CD271 + MSCs obtained from wild-type dogs were pretreated with FK228 and then cultured for 2 days with the adenovirus vectors (Ad-cMyoD or Ad-eGFP, multiplicity of infection = 25, ref. 50). These cells were washed and maintained in NH expansion medium or DMEM (Invitrogen) containing 2% horse serum, 100 U penicillin/ml, and 100 μg streptomycin/ml for 7-10 days, with a medium change every 3 days.
Myogenic differentiation of
Characterization of DLA genotyping. DNA from blood sampled from the wild-type, carrier and CXMD J was extracted using the DNeasy extraction kit (Qiagen, Crawley, UK). DLA class II typing was performed by means of PCR and sequencing for DLA-DRB1, DQA-1, and DQB-1 alleles. 21 DNA sequence-based typing was used to characterize the dogs.
MSCs transplantation experiments. Allogeneic MSCs were transplanted on day 0 of the experiment. Five days earlier, muscle degeneration and regeneration cycles were induced in the TA muscle of wild-type dogs by the injection of 10.5 nmol CTX (Sigma-Aldrich)/kg. Stable MSC transformants obtained from the DLA-identical recipient wild-type dog were established using RV-Luc expressing luciferase. MSCs were transduced with Ad-MyoD (multiplicity of infection = 50); 2 days later, these cells were injected into the extensor carpi ulnaris and TA muscles. Recipient dogs were given 25 or 8.3 mg oral cyclosporine (Sandimmune; Novartis, E. Hannover, NJ)/kg body weight daily from day 5 until the end of the experiments, and 30 or 10 mg mycophenolate mofetil (CellCept; Roche Laboratories, Nutley, NJ)/kg body weight daily from day 0 until the end of the experiments. 50 The same MSCs were also injected into the extensor carpi ulnaris (1 × 10 6 cells diluted in 1 ml PBS) and TA (2 or 4 × 10 6 cells diluted in 1 ml PBS) muscles of nonimmunosuppressed CXMD J . The injected muscles were then biopsied at 10 days and 4, 8, and 12 weeks after transplantation, or the animals were sacrificed at the end of the experiment. MyoD and eGFP-transduced MSCs (5 × 10 6 cells) were also administered into the femoral artery. Five days after the injection of CTX into the TA muscle of recipient wild-type dogs, the femoral artery was subjected to transient avascularization using a tourniquet, followed by the injection of papaverine hydrochloride (0.44 mg/kg). Serum creatine kinase, C-reactive protein, and cyclosporine concentrations were estimated 1 week after initial treatment and at the time of necropsy. The transplanted muscles were biopsied at 2, 4, or 8 weeks after injection. For biopsy and necropsy, the individual muscle was dissected tendon-to-tendon, divided into several pieces and immediately frozen in liquid nitrogen-cooled isopentane. At least 30 sections from the blocks were analyzed. The dogs underwent periodic veterinary examinations during the experiments. Hematological and serum biochemical testing was performed using a semiautomated hematology analyzer (Sysmex Hematology Analyzer F-820; Sysmex, Hyogo, Japan). Serum alanine aminotransferase, alkaline phosphatase, and creatine kinase, C-reactive protein levels were measured using an automated analyzer (DRI-CHEM3506; Fujifilm, Tokyo, Japan).
Histopathology and immunohistochemistry.
The biopsied muscles were fixed in 15% neutralized formaldehyde-PBS. Transverse cryosections (10-μm thick) prepared from the MSCs-injected muscles were stained with hematoxylin and eosin using standard procedures. For immunohistochemistry, cells cultured on glass coverslips in 24-well plates were fixed in 1% formaldehyde-PBS for 1 hour at 4 °C. Thick cryosections (8-µm thick) prepared from MSCs-injected muscles tissues were fixed in 1% paraformaldehyde-PBS for 30 minutes at 4 °C. Cell monolayers and tissue sections were permeabilized for 5 minutes in PBS containing 0.1% Triton X-100 and then blocked with 3% bovine serum albumin in PBS. The following antibodies were used for antigen detection at 1:50-1:100 dilutions of rabbit anti-MyoD antibodies (Santa Cruz Biotechnology, Delaware, CA): mouse anti-actinin antibodies (EA-53; Sigma-Aldrich), rabbit anti-firefly luciferase antibodies (ab21176; Abcam, Cambridge, UK), chicken anti-GFP antibodies (AB16901; Millipore, Billerica, MA), mouse anti-dMyHC antibodies (NCL-MHCd; Leica, Heidelberg, Germany), or mouse antidystrophin (NCL-DYS3; Leica). All antibodies were diluted with 0.5% bovine serum albumin in PBS and incubated with the cells or tissue sections for either 1 hour at room temperature or overnight at 4 °C. The cells or tissue sections were washed with PBS and then incubated with Alexa 488-or Alexa 568-conjugated anti-mouse IgG antibodies (Invitrogen), Alexa 488-or Alexa 568-conjugated anti-rabbit IgG antibodies (Invitrogen), or Cy3.5-conjugated anti-chicken IgY (IgG) antibodies (ab6962; Abcam) at a 1:500 dilution for 1 hour at 4 °C. Coverslips or glass slides were washed with PBS and mounted in Vectashield (Vector Laboratories, Burlingame, CA) with 4′, 6′-diamidino-2-phenylindole. Immunofluorescence was visualized using an IX71 fluorescence microscope (Olympus, Tokyo, Japan).
Reverse transcriptase-PCR. Total RNA (1 μg) from cultured MSCs or muscle samples disrupted in a Multi-Beads Shocker (Yasui Kikai, Osaka, Japan) was isolated using the RNeasy Micro kit (Qiagen). First-strand complementary DNA was synthesized using a Super Script III First-Strand Synthesis System for reverse transcriptase-PCR (Invitrogen). From the 20 μl complementary DNA reaction volume, 0.5-2 μl were used for each PCR assay. The primers used in this study were as follows: developmental myosin heavy chain: forward, 5′-gcatcgagtggaccttcattgac-3′, and reverse, 5′-acagtctcattgagagggt ccttg-3′; myogenin: forward, 5′-acgagcggactgagctcagcc-3′, and reverse, 5′-ggtagcggaggtcccgctcctcctggttgag-3′; MyoD: forward, 5′-atggagcttcta tcgccgccac-3′, and reverse, 5′-aggcctcattcactttgctcag-3′; dystrophin: forward, 5′-gattctcctgagctgggtccgac-3′, and reverse, 5′-gccttggcaacatttccacttcctg-3′; and eGFP: forward, 5′-gtgagcaagggcgaggag-3′, and reverse, 5′-gtggtgcagatgaacttcagg -3′. As an internal control, a primer set of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase or TATAbinding protein was used. complementary DNA was amplified using an Ampli Taq Gold 360 Master (Applied Biosystems, Tokyo, Japan) and primers, with a total of 40 cycles. PCR products were resolved by agarose gel electrophoresis. The eGFP gene was amplified using SYBR Premix Ex TaqII (Perfect Real Time; Takara Bio) for 60 cycles. Quantitative PCR was carried out using SYBR green detection of PCR products in real time with the MyiQ single-color detection system (Bio-Rad, Hercules, CA). Figure S1 . Flow cytometry analysis of fresh or cultured CD271 + and CD271 − cells. Figure S2 . Characterization of CD271 + MSCs derived from CXMD J . Figure S3 . Immunofluorescence staining of intra-arterially injected CD271 + MSCs engrafted in the heart of a recipient dog. Figure S4 . Immunofluorescence staining of lymphocytes from muscle injected with CD271 + MSCs. Figure S5 . Immunoblotting for the detection of dystrophin antibody. Materials and Methods.
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